All In Biotech

Drug Trial Radar · NCT00783432

Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis

Active-Controlled Trial of the Safety and Tolerability of a MP03-33 in Patients With Chronic Allergic or Nonallergic Rhinitis

Last checked: Nov 19, 2026Latest source record: Oct 6, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 862 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

862

Actual

Start

Jul 2006

Primary completion

Dec 2007

Study completion Dec 2007

Sponsor

Lead sponsor
Meda PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Oct 31, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if Astepro Nasal Spray (0.1% azelastine hydrochloride) is as safe as Astelin Nasal Spray (0.1% azelastine hydrochloride)

Conditions

  • Chronic Allergic Rhinitis
  • Nonallergic Rhinitis

Interventions

  • Astepro Nasal Spray (0.1% azelastine hydrochloride)Drug

    548 mcg (2 sprays per nostril) twice a day

  • Astelin Nasal Spray (0.1% azelastine hydrochloride)Drug

    548 mcg (2 sprays per nostril) twice a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Reporting Adverse EventsTime frame: 12 months
  2. Focused Examination of the Head and Neck With Findings Recorded on a Numeric Scale.Time frame: baseline and 12 months/ET

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Meda Clinical Trials Contact Center

    Somerset, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.